ZA200307413B - Recovery of enzyme activity from enveloped viruses. - Google Patents
Recovery of enzyme activity from enveloped viruses. Download PDFInfo
- Publication number
- ZA200307413B ZA200307413B ZA200307413A ZA200307413A ZA200307413B ZA 200307413 B ZA200307413 B ZA 200307413B ZA 200307413 A ZA200307413 A ZA 200307413A ZA 200307413 A ZA200307413 A ZA 200307413A ZA 200307413 B ZA200307413 B ZA 200307413B
- Authority
- ZA
- South Africa
- Prior art keywords
- virus
- substance
- activity
- cysteine
- plasma
- Prior art date
Links
- 230000000694 effects Effects 0.000 title claims description 91
- 241000700605 Viruses Species 0.000 title claims description 53
- 102000004190 Enzymes Human genes 0.000 title claims description 52
- 108090000790 Enzymes Proteins 0.000 title claims description 52
- 238000011084 recovery Methods 0.000 title claims description 13
- 102100034343 Integrase Human genes 0.000 claims description 120
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 120
- 210000002381 plasma Anatomy 0.000 claims description 64
- 239000000126 substance Substances 0.000 claims description 58
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 32
- 239000000523 sample Substances 0.000 claims description 23
- 239000000872 buffer Substances 0.000 claims description 21
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 15
- 229940033663 thimerosal Drugs 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 230000003612 virological effect Effects 0.000 claims description 14
- 238000011534 incubation Methods 0.000 claims description 13
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 11
- 239000012472 biological sample Substances 0.000 claims description 10
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims description 10
- 229960003151 mercaptamine Drugs 0.000 claims description 10
- 230000000415 inactivating effect Effects 0.000 claims description 9
- 230000002934 lysing effect Effects 0.000 claims description 9
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 claims description 8
- XYONNSVDNIRXKZ-UHFFFAOYSA-N S-methyl methanethiosulfonate Chemical compound CSS(C)(=O)=O XYONNSVDNIRXKZ-UHFFFAOYSA-N 0.000 claims description 8
- 235000018417 cysteine Nutrition 0.000 claims description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 8
- 239000003638 chemical reducing agent Substances 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 5
- 230000009089 cytolysis Effects 0.000 claims description 5
- 239000003599 detergent Substances 0.000 claims description 5
- 239000011159 matrix material Substances 0.000 claims description 5
- NBCQBGBECVUZMK-UHFFFAOYSA-N (4-carboxyphenyl)mercury;hydrate Chemical compound O.OC(=O)C1=CC=C([Hg])C=C1 NBCQBGBECVUZMK-UHFFFAOYSA-N 0.000 claims description 4
- NQUNIMFHIWQQGJ-UHFFFAOYSA-N 2-nitro-5-thiocyanatobenzoic acid Chemical compound OC(=O)C1=CC(SC#N)=CC=C1[N+]([O-])=O NQUNIMFHIWQQGJ-UHFFFAOYSA-N 0.000 claims description 4
- 108010024636 Glutathione Proteins 0.000 claims description 4
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims description 4
- 241000713666 Lentivirus Species 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 239000010839 body fluid Substances 0.000 claims description 4
- 229960003180 glutathione Drugs 0.000 claims description 4
- NJRXVEJTAYWCQJ-UHFFFAOYSA-N thiomalic acid Chemical compound OC(=O)CC(S)C(O)=O NJRXVEJTAYWCQJ-UHFFFAOYSA-N 0.000 claims description 4
- 241001430294 unidentified retrovirus Species 0.000 claims description 4
- 241000712907 Retroviridae Species 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 150000001450 anions Chemical group 0.000 claims description 2
- 238000001952 enzyme assay Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 2
- 229940088598 enzyme Drugs 0.000 description 43
- 239000000499 gel Substances 0.000 description 26
- 238000002976 reverse transcriptase assay Methods 0.000 description 14
- 230000000903 blocking effect Effects 0.000 description 12
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 11
- 230000001177 retroviral effect Effects 0.000 description 11
- 210000002845 virion Anatomy 0.000 description 11
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
- 241000881705 Porcine endogenous retrovirus Species 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 241000713326 Jaagsiekte sheep retrovirus Species 0.000 description 5
- 230000003750 conditioning effect Effects 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 description 5
- 229940124024 weight reducing agent Drugs 0.000 description 5
- 238000007792 addition Methods 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108020000999 Viral RNA Proteins 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 108091092356 cellular DNA Proteins 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 210000004779 membrane envelope Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 2
- WCKKVBDZUVPNNY-UHFFFAOYSA-N 2-(2-aminoethylsulfonylsulfanyl)ethanamine Chemical compound NCCSS(=O)(=O)CCN WCKKVBDZUVPNNY-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000012554 Fractogel® EMD TMAE Hicap (M) Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- 229940096826 phenylmercuric acetate Drugs 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- OAKPWEUQDVLTCN-NKWVEPMBSA-N 2',3'-Dideoxyadenosine-5-triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1 OAKPWEUQDVLTCN-NKWVEPMBSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 1
- GFZXQBDELXEPTQ-UHFFFAOYSA-N 3-[(3-carboxy-2-nitrophenyl)disulfanyl]-2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC(SSC=2C(=C(C(O)=O)C=CC=2)[N+]([O-])=O)=C1[N+]([O-])=O GFZXQBDELXEPTQ-UHFFFAOYSA-N 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241001493147 Bwamba orthobunyavirus Species 0.000 description 1
- 241001493160 California encephalitis virus Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 239000012605 Fractogel® EMD TMAE Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 241000701377 Iridoviridae Species 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000713124 Rift Valley fever virus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241001135555 Sandfly fever Sicilian virus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- HDRRAMINWIWTNU-NTSWFWBYSA-N [[(2s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-NTSWFWBYSA-N 0.000 description 1
- ARLKCWCREKRROD-POYBYMJQSA-N [[(2s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 ARLKCWCREKRROD-POYBYMJQSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- URGJWIFLBWJRMF-JGVFFNPUSA-N ddTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 URGJWIFLBWJRMF-JGVFFNPUSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000291 inelastic electron tunnelling spectroscopy Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0101219A SE0101219D0 (sv) | 2001-04-05 | 2001-04-05 | Recovery of enzyme activity from enveloped viruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200307413B true ZA200307413B (en) | 2004-09-23 |
Family
ID=20283685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200307413A ZA200307413B (en) | 2001-04-05 | 2003-09-23 | Recovery of enzyme activity from enveloped viruses. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7566529B2 (de) |
| EP (1) | EP1373897B1 (de) |
| JP (1) | JP4364512B2 (de) |
| CN (1) | CN1255550C (de) |
| AP (1) | AP1823A (de) |
| AT (1) | ATE410689T1 (de) |
| AU (1) | AU2002249715B8 (de) |
| BR (1) | BRPI0208542B8 (de) |
| DE (1) | DE60229222D1 (de) |
| EA (1) | EA006740B1 (de) |
| ES (1) | ES2315357T3 (de) |
| HK (1) | HK1063073A1 (de) |
| MX (1) | MXPA03009060A (de) |
| OA (1) | OA12460A (de) |
| PT (1) | PT1373897E (de) |
| SE (1) | SE0101219D0 (de) |
| WO (1) | WO2002082088A1 (de) |
| ZA (1) | ZA200307413B (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1808697A1 (de) * | 2006-01-13 | 2007-07-18 | Novartis Vaccines and Diagnostics, Inc. | Verwendung einer Ionenaustauschmatrix zur Bestimmung der Konzentration von Viruspartikeln und/oder Virusantigenen |
| US10920288B2 (en) | 2015-01-16 | 2021-02-16 | Takeda Vaccines, Inc. | Detection of particle-contained reverse transcriptase activity |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4707439A (en) * | 1984-10-26 | 1987-11-17 | The United States Of America As Represented By The Department Of Health And Human Services | Screening test for reverse-transcriptase containing virus such as non-A, non-B hepatitis, NANBH |
| SE0001132D0 (sv) * | 2000-03-29 | 2000-03-29 | Cavidi Tech Ab | Method of concentrating and recovering a viral enzyme activity from biological samples |
-
2001
- 2001-04-05 SE SE0101219A patent/SE0101219D0/xx unknown
-
2002
- 2002-03-27 EP EP02718732A patent/EP1373897B1/de not_active Expired - Lifetime
- 2002-03-27 EA EA200300961A patent/EA006740B1/ru not_active IP Right Cessation
- 2002-03-27 CN CNB028110889A patent/CN1255550C/zh not_active Expired - Fee Related
- 2002-03-27 AP APAP/P/2003/002893A patent/AP1823A/en active
- 2002-03-27 AU AU2002249715A patent/AU2002249715B8/en not_active Ceased
- 2002-03-27 OA OA1200300243A patent/OA12460A/en unknown
- 2002-03-27 US US10/472,756 patent/US7566529B2/en not_active Expired - Lifetime
- 2002-03-27 ES ES02718732T patent/ES2315357T3/es not_active Expired - Lifetime
- 2002-03-27 WO PCT/SE2002/000612 patent/WO2002082088A1/en active Application Filing
- 2002-03-27 BR BRPI0208542A patent/BRPI0208542B8/pt not_active IP Right Cessation
- 2002-03-27 DE DE60229222T patent/DE60229222D1/de not_active Expired - Lifetime
- 2002-03-27 MX MXPA03009060A patent/MXPA03009060A/es active IP Right Grant
- 2002-03-27 PT PT02718732T patent/PT1373897E/pt unknown
- 2002-03-27 AT AT02718732T patent/ATE410689T1/de active
- 2002-03-27 JP JP2002579807A patent/JP4364512B2/ja not_active Expired - Fee Related
-
2003
- 2003-09-23 ZA ZA200307413A patent/ZA200307413B/en unknown
-
2004
- 2004-07-02 HK HK04104779.5A patent/HK1063073A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002249715B8 (en) | 2006-12-07 |
| EP1373897A1 (de) | 2004-01-02 |
| JP2004527246A (ja) | 2004-09-09 |
| CN1513116A (zh) | 2004-07-14 |
| DE60229222D1 (de) | 2008-11-20 |
| EP1373897B1 (de) | 2008-10-08 |
| OA12460A (en) | 2006-05-24 |
| BR0208542B1 (pt) | 2014-06-17 |
| BR0208542A (pt) | 2004-03-02 |
| EA200300961A1 (ru) | 2004-04-29 |
| ES2315357T3 (es) | 2009-04-01 |
| EA006740B1 (ru) | 2006-04-28 |
| AP2003002893A0 (en) | 2003-12-31 |
| AU2002249715B2 (en) | 2006-10-19 |
| JP4364512B2 (ja) | 2009-11-18 |
| MXPA03009060A (es) | 2004-02-17 |
| US20040110265A1 (en) | 2004-06-10 |
| CN1255550C (zh) | 2006-05-10 |
| ATE410689T1 (de) | 2008-10-15 |
| WO2002082088A1 (en) | 2002-10-17 |
| HK1063073A1 (en) | 2004-12-10 |
| AP1823A (en) | 2008-01-31 |
| SE0101219D0 (sv) | 2001-04-05 |
| US7566529B2 (en) | 2009-07-28 |
| BRPI0208542B8 (pt) | 2021-07-27 |
| PT1373897E (pt) | 2008-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schiebel et al. | RNA-directed RNA polymerase from tomato leaves. I. Purification and physical properties | |
| Quadt et al. | Characterization of a host protein associated with brome mosaic virus RNA-dependent RNA polymerase. | |
| Boyer et al. | HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors | |
| Stetler et al. | T4 DNA-delay proteins, required for specific DNA replication, form a complex that has ATP-dependent DNA topoisomerase activity. | |
| SALLAFRANQUE‐ANDREOLA et al. | Human immunodeficiency virus reverse transcriptase expressed in transformed yeast cells: Biochemical properties and interactions with boyine tRNALys | |
| Gorelick et al. | Characterization of the block in replication of nucleocapsid protein zinc finger mutants from Moloney murine leukemia virus | |
| Larder et al. | Properties of purified enzymes induced by pathogenic drug-resistant mutants of herpes simplex virus. Evidence for virus variants expressing normal DNA polymerase and altered thymidine kinase. | |
| Siedlecki et al. | Characterization of a prokaryotic topoisomerase I activity in chloroplast extracts from spinach | |
| Haseltine et al. | Interaction of tryptophan tRNA and avian myeloblastosis virus reverse transcriptase: further characterization of the binding reaction | |
| Abboud et al. | The DNA polymerases associated with the adenovirus type 2 replication complex: effect of 2′-3′-dideoxythymidine-5′-triphosphate on viral DNA synthesis | |
| Urban et al. | Efficient pyrophosphorolysis by a hepatitis B virus polymerase may be a primer-unblocking mechanism | |
| WO1990006320A1 (en) | Substrate for polymerase activity determination | |
| Seifried et al. | Characterization of an RNA-dependent RNA polymerase activity associated with measles virus | |
| US7566529B2 (en) | Method for the recovery of retroviral reverse transcriptase (RT) activity from a sample containing unprotected cellular polymerases | |
| Moen et al. | T4 phage deoxyribonucleoside triphosphate synthetase: purification of an enzyme complex and identification of gene products required for integrity | |
| AU2002249715A1 (en) | Recovery of enzyme activity from enveloped viruses | |
| Hirschman et al. | Ionic requirements of the DNA polymerase associated with serum hepatitis B antigen | |
| Miwa et al. | Reconstituted F1-ATPase complexes containing one impaired β subunit are ATPase-active | |
| AU2002303065B2 (en) | A method for measuring DNA polymerization and applications of the method | |
| Harvey et al. | Search for multienzyme complexes of DNA precursor pathways in uninfected mammalian cells and in cells infected with herpes simplex virus type I | |
| Lennerstrand et al. | A method for combined immunoaffinity purification and assay of HIV-1 reverse transcriptase activity useful for crude samples | |
| Kraus et al. | Simian immunodeficiency virus reverse transcriptase: Purification and partial characterization | |
| EP1268851B1 (de) | Verfahren zum konzentrieren und wiederfinden von viraler enzymaktivität in biologischen proben | |
| Dunham et al. | DNA polymerase activities in healthy and cauliflower mosaic virus-infected turnip (Brassica rapa) plants | |
| JP4455054B2 (ja) | ウイルス薬剤感受性の検査法 |